Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director · President and CEO | June 03, 2026 | June 05, 2026 |
| VSE CORPVSEC · Entity 3833 | Senior Vice President and CFO | March 31, 2024 | April 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,742 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 12,840 · Balance 49,742 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F2: Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 45,973 |
Reported balance
After 2026-06-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-03 · Tax withholding · Disposed 3,769 · Balance 45,973 F3: Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 12,840 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Exercise / conversion · Disposed 12,840 · Balance 12,840 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F4: On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
F2: Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.
F3: Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.
F4: On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.
VSE CORP
Report date March 31, 2024 · Filed April 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.05SEC Table I · non-derivative | Direct | 28,763 |
Ending reported balance
After 2024-04-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-03-31 · Grant · Acquired 2,567 · Balance 28,636 F1: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2023. Row 2 · 2024-03-31 · Exercise / conversion · Acquired 1,287 · Balance 29,923 F2: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Row 3 · 2024-04-01 · Tax withholding · Disposed 1,160 · Balance 28,763 F3: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2023.
F2: Represents acquisition of shares of VSE common stock upon vesting of RSUs.
F3: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2021 Filed Jan 3, 2022 20:17 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 204 | $44.04 | $8,984.16 |
DisclosureSEC source: 0001831125-22-000001 · primary_doc.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,515 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the VSE Corporation 2021 Employee Stock Purchase Plan. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 11:50 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001868979-21-000001 · primary_doc.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,311 Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 19:03 UTC | VSE CORP vsec · Entity 3833 | GrantRestricted Stock Units · Derivative | 3,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001450186-21-000017 · primary_doc.xml · derivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,863 Underlying: Common Stock · 3,863 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VSEC common stock. F2 · derivative.exercise_date: The restricted stock units generally vest in substantially equal installments on each of March 31, 2022, March 31, 2023 and March 31, 2024. F2 · derivative.expiration_date: The restricted stock units generally vest in substantially equal installments on each of March 31, 2022, March 31, 2023 and March 31, 2024. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 19:51 UTC | VSE CORP vsec · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 24 | $41.42 | $994.08 |
DisclosureSEC source: 0001450186-21-000009 · primary_doc.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,311 Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 19:51 UTC | VSE CORP vsec · Entity 3833 | GrantCommon Stock, par value $.05 | 67 | $0.00 | $0.00 |
DisclosureSEC source: 0001450186-21-000009 · primary_doc.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335 Read SEC document |
| November 16, 2020 Filed Nov 16, 2020 16:55 UTC | VSE CORP vsec · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 1,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001450186-20-000026 · primary_doc.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,268 Read SEC document |
| November 16, 2020 Filed Nov 16, 2020 16:55 UTC | VSE CORP vsec · Entity 3833 | GrantCommon Stock, par value $.05 | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001450186-20-000026 · primary_doc.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.